Kura Oncology, Inc. (KURA) - Utang jangka dawa marang modal

Kura Oncology, Inc. (KURA) operates in a clinical research mode, relying on venture capital infusions due to the absence of stable cash flow. Business prospects depend on FDA approval of ziftomenib and the results of leukemia trials. This chart of the long-term debt-to-equity ratio reflects 0.39, which is critical for a company developing targeted oncology treatments and precision therapies.

The development of Ziftomenib and expansion into leukemia therapy require significant capital expenditures, making the long-term debt-to-equity ratio a key indicator of financial stability for Kura Oncology, Inc. (KURA). This ratio compares liabilities with maturities exceeding one year against shareholders' equity, allowing investors to assess leverage risk and the company's ability to scale its business without critical pressure from interest rates.